Alkermes Issues FY20 Outlook In Line With Estimates - Quick Facts

(RTTNews) - While reporting its financial results for the fourth quarter on Thursday, Alkermes Plc (ALKS) forecast fiscal 2020 net loss in a range of $0.82 to $1.01 per share, adjusted earnings of $0.25 to $0.43 per share, and total revenues to range from $1.03 billion to $1.08 billion.

Excluding license and R&D revenues from Biogen of about $195 million related to the development and approval of Vumerity recorded in 2019, this represents revenue growth of approximately 8 percent.

The company noted that the full-year outlook reflects the expected impact of the strategic restructuring implemented in 2019.